Publications by authors named "Kristian Buch-Larsen"
Article Synopsis
- Breast cancer patients experience a heightened risk of cardiometabolic diseases, exacerbated by adjuvant therapies that alter inflammatory and metabolic health markers.
- A study measured inflammatory cytokines and metabolic health parameters in 51 postmenopausal early breast cancer patients over two years, revealing significant increases in cytokines immediately after chemotherapy.
- Although cytokine levels returned to near baseline within six months, patients continued to show worsened lipid profiles and insulin resistance for up to a year post-treatment.
Article Synopsis
- This study investigated thyroid function changes in women with early breast cancer undergoing adjuvant chemotherapy and examined the relationship to weight gain and autoimmune conditions.* -
- Results showed increased thyroid-stimulating hormone and decreased free-thyroxine levels post-chemotherapy, but no significant changes in body weight or evidence of autoimmune thyroiditis were found.* -
- The researchers concluded that while thyroid hormone changes occurred, they didn't indicate clinically significant thyroid dysfunction, and further research is necessary to explore long-term effects following treatment.*
Article Synopsis
- The study focuses on postmenopausal women who have survived early breast cancer (EBC) and their metabolic responses after chemotherapy, comparing them to healthy controls.
- Researchers hypothesize that chemotherapy adversely affects the metabolism of these women, affecting how their bodies absorb and process nutrients after eating.
- Though there were no statistically significant differences in metabolic markers between EBC patients and controls, some trends indicate higher insulin levels and altered fatty acid responses in EBC patients during the post-meal period.
Chronic non-bacterial osteomyelitis (CNO) is an autoinflammatory, osteolytic bone disorder sometimes localized to a unifocal site in the jaw, causing long-term pain and reduced function. The aim of this study was to describe the patients with CNO of the jaw, focusing on treatment with zoledronic acid for pain relief. An analysis of medical records of 24 patients with CNO of the jaw, including treatment with zoledronic acid and effects on pain relief.
View Article and Find Full Text PDFBackground: Adjuvant chemo- and radiotherapy cause cellular damage to tumorous and healthy dividing cells. Chemotherapy has been shown to cause mitochondrial respiratory dysfunction in non-tumorous tissues, but the effects on human peripheral blood mononuclear cells (PBMCs) remain unknown.
Aim: We aimed to investigate mitochondrial respiration of PBMCs before and after adjuvant chemo- and radiotherapy in postmenopausal patients with early breast cancer (EBC) and relate these to metabolic parameters of the patients.
Introduction: Breast cancer (BC) is a common type of cancer in women. Advances in therapy options have resulted in higher overall survival rates but side effects of cancer treatment are increasingly in the spotlight. The beneficial effects of anti-oestrogen therapy with tamoxifen and letrozole in the prevention of BC recurrence are well documented.
View Article and Find Full Text PDFWomen with breast cancer are a growing population due to improved screening and treatment. It has been described that chemotherapy can negatively affect patients' metabolism. The aim of this study is to assess weight gain during chemotherapy treatment in an interim analysis on an ongoing prospective cohort of women with early breast cancer.
View Article and Find Full Text PDFPurpose: Chemotherapy-induced peripheral neuropathy (CIPN) is a recognized adverse effect of standard (neo)adjuvant chemotherapy in breast cancer (BC) treatment. However, there is no consensus on a validated method for assessing CIPN. Heart rate variability (HRV) and vibration perception threshold (VPT) could be used as objective measures to describe CIPN.
View Article and Find Full Text PDFArticle Synopsis
- - The study examines the efficacy of denosumab as a second-line treatment for post-menopausal women with early breast cancer who cannot receive standard intravenous zoledronic acid (ZA), focusing on its effects on bone mineral density (BMD) and markers of bone turnover.
- - A total of 194 women were followed for up to 24 months after being offered either denosumab or ZA, with both treatments showing similar suppression of bone turnover markers and modest increases in BMD at certain sites for denosumab.
- - The findings suggest that denosumab could be considered a valid alternative to ZA for managing bone density in breast cancer patients undergoing aromatase inhibitor treatment, especially for those at risk of developing osteoporosis.
Metabolic dysfunction is a comorbidity of many types of cancers. Disruption of glucose metabolism is of concern, as it is associated with higher cancer recurrence rates and reduced survival. Current evidence suggests many health benefits from exercise during and after cancer treatment, yet only a limited number of studies have addressed the effect of exercise on cancer-associated disruption of metabolism.
View Article and Find Full Text PDFBackground: It is well known that breast cancer (BC) patients often suffer from chemotherapy-induced peripheral neuropathy (CIPN). However, it is not always recognized that they have higher risk of falling, dizziness and other signs of dysfunctional autonomous nervous system. We performed a systematic review of the literature on vibration perception threshold (VPT) and heart rate variability (HRV) as methods to objectively assess (CIPN) in BC-patients.
View Article and Find Full Text PDF